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ody dysmorphic disorder (BDD) is a DSM-IV
disorder that is characterized by a distressing or impair-
ing preoccupation with slight or imagined defect(s) in
one’s physical appearance. BDD has been consistently
described around the world for more than a century.
1,2
Enrico Morselli, an Italian physician who called this
disorder “dysmorphophobia,” offered this poignant
description in 1891: “The dysmorphophobic patient is
really miserable; in the middle of his daily routines,
conversations, while reading, during meals, in fact
everywhere and at any time, is overcome by the fear of
deformity… which may reach a very painful intensity,
even to the point of weeping and desperation”.
3 BDD
was later described by distinguished psychiatrists such
as Emil Kraepelin and Pierre Janet
4,5 and, over the
years, numerous case studies have been reported from
around the world.
6
Despite its long history, BDD has been researched in
a sustained and systematic way for less than two
decades. During this time, much has been learned
about the disorder, including its clinical features, epi-
demiology, and treatment. While still very preliminary,
data are beginning to emerge on BDD’s neurocogni-
tive deficits and underlying neurobiology. BDD is
becoming better known, but it remains underrecog-
nized.
7-11 Because BDD causes substantial suffering
and impairment in functioning, there is a need for
increased recognition of this often-debilitating condi-
tion across all specialties.
12
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Body dysmorphic disorder (BDD) is a relatively common
disorder that consists of a distressing or impairing pre-
occupation with imagined or slight defects in appear-
ance. BDD is commonly considered to be an obsessive-
compulsive spectrum disorder, based on similarities it has
with obsessive-compulsive disorder. It is important to rec-
ognize and appropriately treat BDD, as this disorder is
associated with marked impairment in psychosocial func-
tioning, notably poor quality of life, and high suicidality
rates. In this review, we provide an overview of research
findings on BDD, including its epidemiology, clinical fea-
tures, course of illness, comorbidity, psychosocial func-
tioning, and suicidality. We also briefly review recent
research on neural substrates and cognitive processing.
Finally, we discuss treatment approaches that appear
efficacious for BDD, with a focus on serotonin-reuptake
inhibitors and cognitive-behavioral therapy.  
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Here we provide DSM-IV’s definition of BDD and
briefly comment on each diagnostic criterion.
A) “Preoccupation with an imagined defect in appear-
ance. If a slight physical anomaly is present, the person’s
concern is markedly excessive.” The most common pre-
occupations focus on the skin (eg, scarring, acne, color),
hair (eg, going bald, excessive facial or body hair), or
nose (eg, size or shape), although any body part can be
the focus of concern.
13“Preoccupation” in criterion A is
not operationalized, but it is often defined as thinking
about the perceived appearance defect(s) for at least 1
hour a day (similar to obsessive-compulsive disorder
[OCD]).
1,14,15
B) “The preoccupation causes clinically significant dis-
tress or impairment in social, occupational, or other
important areas of functioning.” As in other disorders,
distress and impairment in functioning vary in terms of
severity. But typically, patients experience substantial
impairment in social, occupational, and academic func-
tioning, as will be discussed later in this review. 
C) “The preoccupation is not better accounted for by
another mental disorder (eg, dissatisfaction with body
shape and size in anorexia nervosa).” This criterion indi-
cates that if a person’s only appearance concern is that
he/she weighs too much or is too fat, and the person
meets diagnostic criteria for anorexia nervosa or bulimia
nervosa, then the eating disorder, rather than BDD, is
diagnosed. However, BDD and eating disorders are fre-
quently comorbid, in which case both disorders should
be diagnosed.
16,17
DSM first included BDD in the third edition (DSM-III),
where it was called “dysmorphophobia.”
18 In DSM-III, it
was an example of an atypical somatoform disorder (the
“atypical” designation was similar to DSM-IV’s “Not
Otherwise Specified” category), and diagnostic criteria
were not provided. BDD was first given diagnostic cri-
teria, and classified as a separate disorder (a somatoform
disorder), in DSM-III-R, where it was called “body dys-
morphic disorder.”
19 In the current edition of DSM
(DSM-IV-TR), BDD is also classified as a somatoform
disorder.
15 ICD-10 classifies BDD, along with hypochon-
driasis, as a type of “hypochondriacal disorder,” also in
the somatoform section.
20 During the DSM-IV develop-
ment process, consideration was given to moving BDD
to the anxiety disorders section of DSM, but there were
insufficient data at that time to determine whether this
change was warranted.
21 Under consideration for DSM-5
is whether BDD might be included in a section of
“Anxiety and Obsessive-Compulsive Spectrum
Disorders,” although it is not yet known whether such a
section will be included in DSM-5.
22
A clinically important issue is how BDD’s delusional
variant (in which patients are completely convinced that
they appear ugly or abnormal) should be classified. In
DSM-IV, BDD’s delusional variant is classified as a type
of delusional disorder, somatic type, in the psychosis sec-
tion of the manual.
15 However, DSM-IV allows BDD
and its delusional disorder variant to be doublecoded; in
other words, patients with delusional BDD can receive
a diagnosis of both delusional disorder and BDD.
15This
double coding reflects evidence that BDD’s delusional
and nondelusional variants may in fact be variants of the
same disorder.
7,23,24 Importantly, BDD’s delusional vari-
ant appears to respond to treatment with serotonin-
reuptake inhibitor (SRI) monotherapy, and, although
data are very preliminary, treatment with neuroleptics
does not appear promising.
25,26 During the DSM-5 devel-
opment process, consideration is being given to com-
bining BDD’s delusional variant with its nondelusional
variant into one disorder (BDD) while specifying degree
of insight (with good or fair insight, with poor insight, or
with delusional BDD beliefs).
17
Epidemiology
BDD appears to be relatively common. Epidemiologic
studies have reported a point prevalence of 0.7% to
2.4% in the general population.
27-30These studies suggest
that BDD is more common than disorders such as schiz-
ophrenia or anorexia nervosa.
15 Investigations in non-
clinical adult student samples have yielded higher preva-
lence rates of 2% to 13%.
31-35
BDD is commonly found in clinical settings, with stud-
ies reporting a prevalence of 9% to 12% in dermatology
settings, 3% to 53% in cosmetic surgery settings, 8% to
37% in individuals with OCD, 11% to 13% in social
phobia, 26% in trichotillomania, and 14% to 42% in
atypical major depressive disorder (MDD).
8,36-49 Studies
of psychiatric inpatients have found that 13% to 16% of
patients have DSM-IV BDD.
9,50 A study of adolescent
inpatients found that 4.8% of patients had BDD.
10
These studies indicate that BDD is relatively common.
However, these estimates may underreport its preva-
lence. Many individuals with BDD feel ashamed of their
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As a consequence, they may not report their BDD
symptoms to clinicians. In one study of psychiatric inpa-
tients, only 15.1% had revealed their body image con-
cerns to their mental health clinicians, and the most com-
mon reason for not disclosing their concerns was
embarrassment (in 31.3%).
50 Furthermore, in five stud-
ies in which adults were systematically screened for
BDD, no patient who was found by the researchers to
have BDD had the diagnosis of BDD in their medical
record.
7-11 The number of patients found to have BDD
were as follows: 30 of 30, 11 of 80, 16 of 122, 10 of 208,
and 16 of 122.
Demographic characteristics
BDD has been reported to occur in children as young as
5 and in adults as old as 80.
6,51 Regarding gender ratio,
the two largest population-based studies of BDD (one
conducted in the US; n=2048, and the other conducted
in Germany; n=2552) found a point prevalence of 2.5%
of women vs 2.2% of men, and 1.9% of women and
1.4% of men, respectively.
28,30The largest clinical samples
of persons ascertained for BDD contained an equal pro-
portion of females and males (49% of 188 participants
were female)
52 or a somewhat higher proportion of
females (68.5% of 200 participants).
53 Thus, BDD may
be somewhat more common in women, but it clearly
affects many men as well. 
The two population-based studies cited earlier found
that individuals with BDD are less likely to be married
than those without BDD,
28,30 and are more likely to be
divorced. Individuals with BDD are also significantly
more likely to be unemployed than the general popula-
tion.
28,30 In a sample of 200 individuals with BDD, 37.6%
were currently unemployed.
54
Case description
Ms A, a 32-year-old single white female, was referred by
her dermatologist to a BDD specialty clinic. She lived
alone, was not involved in a romantic relationship, and
had no children. Despite having completed college, she
was employed as a part-time clerk in a clothing boutique.
Ms A attributed her difficulties with obtaining full-time
work to interference she experienced from intrusive
thoughts and compulsive behaviors related to her
appearance concerns.
Ms A looked normal but had been preoccupied with the
appearance of her skin (minor blemishes and “uneven”
skin tone) since age 13. She reported thinking about her
appearance for at least 7 to 8 hours a day, and she wor-
ried that other people would notice her or judge her
negatively because her skin looked so “ugly.” For 5 to 6
hours a day, Ms. A checked her skin in mirrors and other
reflecting surfaces, picked her skin, and compared her
skin with that of other people. She spent thousands of
dollars a year on skin-care products, and she frequently
bought special lighting and mirrors to better examine
her skin. 
Because she was so preoccupied with, and distressed by,
her skin, Ms A was often late for work, and her produc-
tivity suffered, which resulted in conflicts with her super-
visor. She often got “stuck” in the mirror at work, exam-
ining her skin. Because Ms A was so embarrassed about
how she looked, and feared that other people would
judge her negatively (eg, as “abnormal looking” and
“hideous”), Ms A avoided all contact with friends and
saw her family only on special occasions. Ms A reported
feeling anxious and depressed over her skin. She also
expressed passive suicidal ideation because she thought
her skin looked so ugly.
Ms A had seen several dermatologists for treatment to
improve her skin’s appearance. Her compulsive skin
picking was intended to improve perceived skin flaws by
“smoothing” her skin and removing tiny blemishes.
However, because her skin picking was difficult to con-
trol and occurred for several hours a day, this behavior
caused skin irritation and slight redness and scarring. Ms
A had undergone three dermatologic procedures but
continued to be “obsessed” with improving the quality
of her skin. “I just want to look normal!” she stated. Ms
A reported that the dermatologic procedures had done
little to change her perception of her skin’s appearance
and made her feel even more anxious and preoccupied.
This was the first time Ms A had sought mental health
treatment for her skin concerns. In the past, she had
been reluctant to discuss her concerns with a mental
health clinician for fear that she would be perceived as
“superficial” or “vain.”
Appearance preoccupations
The most frequent body areas of concern are the skin
(73%), hair (56%), and nose (37%).
52,55 However, any
body area can be the focus of preoccupation. On aver-
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pied with 5 to 7 different body parts.
52,55 Some individu-
als are preoccupied with their overall appearance; this
includes the muscle dysmorphia form of BDD which
consists of the belief that one’s body is too small and
inadequately muscular.
56-58
Approximately 40% of individuals with BDD actively
think about the disliked body parts for 3 to 8 hours per
day, and 25% report thinking about them for more than
8 hours per day.
6 These preoccupations are almost
always difficult to resist or control, and they are intru-
sive and associated with significant anxiety and distress.
1
Insight regarding perceived 
appearance defects
Insight regarding the perceived appearance defects
varies. In one sample, 35.6% of participants were classi-
fied on the reliable and valid Brown Assessment of
Beliefs Scale (BABS
59) as delusional—that is, completely
certain that their beliefs about how they look were accu-
rate.
60 Prior to effective treatment, few patients have
good insight. Studies have consistently found that insight
is poorer in BDD than in OCD, with 27% to 60% of
BDD patients having delusional beliefs versus only 2%
of OCD patients.
13,61
About two thirds of BDD patients have past or current
ideas or delusions of reference, believing that other peo-
ple take special notice of them in a negative way or
mock or ridicule them because of how they look.
23
Clinical impressions indicate that such referential think-
ing may lead to feelings of rejection and to anger (even
violence, such as attacking someone they believe is
mocking them).
1
As previously noted, patients with delusional BDD
beliefs would receive a DSM-IV-TR diagnosis of delu-
sional disorder, or DSM-IV-TR diagnoses of both delu-
sional disorder and BDD. Studies comparing delusional
and nondelusional BDD patients reveal more similari-
ties than differences between the two groups, and that the
primary difference is BDD symptom severity.
23,25,60
Importantly, delusional BDD appears to respond to SRI
monotherapy and may not respond to antipsychotic med-
ications, suggesting (from a treatment perspective) that
delusional BDD is not a typical psychotic disorder.
26Thus,
it may be more accurate to view insight as existing on a
continuum and to consider BDD to encompass both
delusional and nondelusional appearance beliefs.
62
Furthermore, some individuals with BDD describe fluc-
tuations in insight, such that they are completely con-
vinced that they are ugly at some times but not convinced
at others.
6As one patient remarked: “Some days I think
my skin’s not so bad, but other days I’m convinced.”
1
Observations such as these offer further support for the
view that delusional BDD and nondelusional BDD con-
stitute the same disorder, characterized by a range of
insight, rather than being different disorders. 
Compulsions, safety behaviors, 
and avoidance
The DSM-IV-TR diagnostic criteria for BDD make no
reference to compulsive and safety behaviors that are
commonly associated with BDD; during the DSM-5
development process, consideration is being given to
adding these symptoms to BDD’s diagnostic criteria.
17
Indeed, nearly everyone with BDD performs specific
behaviors—such as mirror checking and skin picking, as
illustrated in the above case—that are linked to their
appearance preoccupations.
52,55The relationship between
thoughts and behaviors in BDD appears similar to the
relationship between obsessions and compulsions in
OCD. That is, the compulsive behaviors arise in response
to the obsessive thoughts about appearance, and are
meant to reduce anxiety and other painful emotions.
13
As in OCD, the behaviors are not pleasurable.
13
These compulsive behaviors are repetitive, time-con-
suming (about half of BDD patients spend 3 or more
hours per day engaged in them), and hard to control and
resist.
63 Some behaviors, such as camouflaging disliked
body parts (eg, with a hat, makeup, sunglasses), are called
safety behaviors, because their function is to reduce or
avoid painful emotions or prevent something bad from
happening, such as being humiliated or embarrassed.
1
Most BDD patients perform multiple compulsive behav-
iors.
52,55 One common behavior is comparing themselves
with other people. Clinical impressions suggest that this
usually happens quite automatically, and can cause anx-
iety and inability to concentrate. About 90% of BDD
patients check themselves repeatedly and excessively in
mirrors or other reflective surfaces.
1Typically, they do this
in the hope that they look acceptable, but often, after see-
ing their reflection, they feel worse.
64 Other common
repetitive behaviors are excessive grooming (eg, comb-
ing their hair or washing their skin repeatedly), tanning
(to improve their skin color or skin imperfections), reas-
Clinical research
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acceptable), excessive shopping for beauty products,
changing their clothes repeatedly to find a more flatter-
ing outfit, and excessive exercise (eg, weightlifting in the
case of muscle dysmorphia).
1,52,55,64-66 Many BDD patients
(27% to 45%) pick at their skin in an attempt to improve
perceived blemishes or imperfections; however, this
behavior sometimes causes observable appearance
defects and can even cause severe damage such as skin
infections and rupture of blood vessels.
67-69 Many other
examples of compulsive behaviors exist, which are often
idiosyncratic, such as drinking more than 3 gallons of
water a day to make one’s face look fuller.
1
Avoidance is a common behavior in BDD.
70,71 Patients
often avoid social situations since they fear being nega-
tively judged by other people because they look “ugly.”
They may not take a job where they think they will be
scrutinized by others. Avoidance may serve a similar pur-
pose as the compulsive behaviors in the short term—that
is, to temporarily relieve BDD-related anxiety and dis-
tress. However, clinical experience indicates that com-
pulsions and avoidance seldom improve anxiety or
reduce the intensity of BDD-related thoughts; rather
these behaviors may contribute to the chronicity and
severity of BDD.
1,72
Course of illness
BDD usually begins during adolescence, with two stud-
ies reporting a mean age at onset of 16 and a mode of
13.
55,73 Retrospective data indicate that BDD appears to
usually have a chronic course, unless it is treated.
52,55 In
what is to our knowledge the only prospective study of
BDD’s course, it was found that the probability of full
remission from BDD over 1 year of follow-up was only
.09, which is lower than has been reported for mood dis-
orders, most anxiety disorders, and personality disorders
in other longitudinal studies.
74 More severe BDD symp-
toms at intake, longer duration of BDD, and the presence
of one or more comorbid personality disorders at intake
predicted a lower likelihood of remission from BDD.
75
Psychosocial functioning and quality of life
BDD is associated with substantial impairment in psy-
chosocial functioning and markedly poor quality of life.
In a sample of 200 individuals with BDD (n=200), 36%
did not work for at least one week in the past month
because of psychopathology, and 11% had permanently
dropped out of school because of BDD symptoms.
54
Individuals with BDD have, on average, much poorer
mental health, emotional well-being, social functioning,
and overall quality of life than the general population, and
scores on quality of life measures are poorer than for
patients with diabetes or clinical depression.
76,77 In the only
prospective study of BDD, overall functioning continued
to be poor over 1 to 3 years, and poorer functioning was
predicted by more severe BDD and greater delusionality
of BDD beliefs at intake.
78 Many patients with more
severe BDD are unable to work, be in or attend school,
or have relationships.
1,54 In two studies, 27% to 31% of
individuals with BDD had been completely housebound
for at least 1 week due to BDD symptoms, and more than
40% had been psychiatrically hospitalized.
52,55
Risk behaviors: suicidality, 
substance abuse, and violence
Rates of suicidal ideation, suicide attempts, and completed
suicide appear markedly elevated.
79Approximately 80%
of individuals with BDD report past or current suicidal
ideation, and about one quarter have attempted suicide,
which is often attributed to BDD symptoms.
42,50,52,79-81 In the
only prospective study of the course of BDD, completed
suicide was reported in 0.3% of cases per year.
82This find-
ing should be considered preliminary, because the sample
size was relatively small and the follow-up period was rel-
atively brief; nonetheless, this suicide rate is markedly ele-
vated. While caution should be used in comparing this
rate to that of other disorders, the standardized mortality
ratio in this study is higher than that reported for nearly
any other mental disorder.
83
Approximately one third of people with BDD report
violent behavior that they attribute primarily to BDD
symptoms (eg, attacking someone or damaging prop-
erty).
1,84 Clinical impressions suggest that anger or vio-
lence may be fueled by anger about looking “deformed,”
inability to fix the “defect,” delusions of reference (eg,
believing that other people are mocking the “defect”),
and feeling rejected by others because of the “defect.”
In addition, anger or even violent behavior may be
caused by dissatisfaction with cosmetic procedures.
According to one survey, 12% of plastic surgeons said
that they had been threatened physically by a dissatis-
fied BDD patient.
85There are occasional reports of indi-
viduals with probable BDD who attacked and even
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outcome of a cosmetic procedure.
2
Many individuals with BDD abuse alcohol or drugs. In
one study,
86 48.9% of BDD participants were diagnosed
with a lifetime substance-use disorder, with 42.6%
reporting an alcohol-use disorder and 30.1% reporting
a cannabis-use disorder. Onset of BDD preceded onset
of a substance-use disorder by at least 1 year in 60% of
the participants, followed onset of the substance-use dis-
order in 19% of the participants, and began in the same
year in 21%. When asked about the relationship between
substance use and BDD symptoms, 68% said that BDD
symptoms contributed to the substance use becoming
problematic.
86
Comorbidity
BDD is often comorbid with other mental disorders. In the
two largest phenomenology studies of individuals ascer-
tained for BDD (n=293 and n=200), which assessed all
participants with the Structured Clinical Interview for
DSM,
14 major depressive disorder was the most common
comorbid disorder, with a lifetime prevalence of about
75% in both samples.
55,73The other most common lifetime
comorbid disorders were substance-use disorders (30% to
48.9%), OCD (32% to 33%), and social phobia (37% to
39%).
55,73,86
BDD in children and adolescents
Even though BDD usually begins before age 18, very
few studies have systematically examined a broad range
of BDD’s clinical features in youth.
87,88 Like adults, youth
report prominent, distressing, and time-consuming
appearance preoccupations as well as prominent appear-
ance-related compulsive behaviors. Nearly all youth
experience impairment in psychosocial functioning that
is attributed primarily to BDD symptoms. In a study of
33 children and adolescents,
87 18% had dropped out of
elementary school or high school primarily because of
BDD symptoms, and in a study of 36 youths, 22% had
dropped out of school primarily because of BDD.
88 Such
difficulties may be particularly problematic during ado-
lescence, because they may substantially interfere with
important adolescent developmental transitions.
1,87,89
Preliminary findings suggest that BDD appears largely
similar in youths and adults; however, in a study that
directly compared adolescents with adults, the adoles-
cents had more delusional beliefs about their appear-
ance, and they were significantly more likely to currently
have a substance-use disorder (30.6% vs 12.8%) and a
history of suicide attempts (44.4% vs 23.8%).
88 In an
adolescent inpatient study, adolescents with BDD
(n=14) scored significantly higher than those without
clinically significant body image concerns (n=140) on the
Suicide Probability Scale, which reflects suicide risk.
10,90
Neural substrates and cognitive processing
Findings from neuropsychological research suggest that
those with BDD overfocus on details of visual stimuli
rather than global aspects.
91 Similarly, an fMRI study of
facial processing found a bias among BDD subjects for
using strategies to encode details of stimuli rather than
use of holistic visual processing strategies.
92These find-
ings are consistent with clinical observations that indi-
viduals with BDD overly focus on minor details of their
appearance, which is theorized to fuel preoccupation with
minor or nonexistent appearance flaws.
1,72,92,93 Recent
research suggests that other information processing
abnormalities are present in BDD, eg, threatening inter-
pretations for nonthreatening scenarios and overestima-
tion of the attractiveness of others’ faces.
94 In studies that
used photographs showing emotional expressions,
94,95
BDD subjects relative to healthy controls tended to mis-
interpret neutral emotional expressions as contemptuous
and angry in scenarios that were self-referent (ie, when
someone was said to be looking at the BDD subject).
94
This finding is consistent with how individuals with BDD
often report ideas or delusions of reference (thoughts
that they are being judged negatively or rejected because
of their appearance). Future research is necessary to
examine this important area further and assess implica-
tions for treatment. 
Additional neuroimaging studies have been done, with
some similar results and some dissimilar results across
studies; findings should be considered preliminary
because sample sizes were small and few studies have
been published. A small MRI study found that BDD
subjects, compared with healthy control participants,
exhibited significantly abnormal asymmetry of the cau-
date nucleus, with a leftward shift in laterality quotient,
as well as greater total white matter volume.
96A second
small study similarly found greater white matter volume
in BDD relative to controls, in addition to smaller
orbitofrontal cortex and anterior cingulate and larger
Clinical research
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97 However, a third study found no sig-
nificant volumetric differences in BDD vs healthy con-
trols.
98 A small BDD single proton-emission computed
tomography study showed relative perfusion deficits in
bilateral anterior temporal and occipital regions and
asymmetric perfusion in the parietal lobes.
99 In another
study, when viewing a photograph of their own face vs a
familiar face, BDD subjects had relative hyperactivity in
left orbitofrontal cortex and bilateral head of the cau-
date compared with controls; frontostriatal activation
correlated with aversiveness ratings of faces and BDD
severity.
100 These results are similar to those in OCD
symptom provocation studies,
101 suggesting that BDD
and OCD symptoms may possibly be mediated by the
same orbitofrontal-subcortical circuit (although this
study did not directly compare BDD and OCD).
Cosmetic treatment for BDD
A majority of individuals with BDD seek (71% to 76%)
and receive (64% to 66%) cosmetic treatment (eg, sur-
gical, dermatologic, or dental) for their perceived appear-
ance flaws.
102,103 In a general population sample from
Germany, 7.2% of those with BDD had received cos-
metic surgery, compared with only 2.8% of those without
BDD.
30 However, such treatment appears to only rarely
improve overall BDD symptoms. In a study of 200 indi-
viduals with BDD, subjects retrospectively reported that
only 3.6% of all treatments resulted in overall improve-
ment in BDD.
102 In another study (n=250), only 7% of
treatments (retrospectively assessed) led to overall
improvement in BDD.
103Veale et al found that 81% of 50
BDD patients were dissatisfied with past medical con-
sultation or surgery.
81 Such an outcome can have serious
negative consequences for both patients and physicians.
In the previously noted survey of cosmetic surgeons, 40%
of respondents indicated that dissatisfied BDD patients
had threatened them physically or legally.
85 It is therefore
important for BDD patients and their mental health
providers to be aware that non-mental health interven-
tions appear unlikely to successfully treat BDD symp-
toms. 
Pharmacotherapy
Pharmacologic treatment for BDD is described in more
detail elsewhere,
1,26 including in a Cochrane review and
a guideline from the United Kingdom’s National
Institute of Clinical Excellence (NICE) on the treatment
of OCD and BDD, which recommend SRIs for the treat-
ment of BDD.
104,105 No medication is approved by the
FDA for the treatment of BDD; studies that are
required for FDA approval have not been conducted in
BDD. Currently, SRIs are recommended as the first-line
medication for BDD, including delusional BDD.
1,26,104,105
Two controlled studies, four open-label trials, and clini-
cal series have reported on SRI efficacy for BDD. All
studies found that these medications are often effica-
cious for BDD.
106-110 In a randomized double-blind par-
allel-group study, fluoxetine was more efficacious than
placebo (d=.70).
111 In a randomized, double-blind
crossover trial, the SRI clomipramine was more effica-
cious than the non-SRI antidepressant desipramine.
106
Four open-label trials (of fluvoxamine, citalopram, and
escitalopram), retrospective studies of a broad range of
SRIs, and case series similarly suggest that SRIs are
often efficacious for BDD and associated symptoms.
7,107-
109,112-115
SRI antidepressants appear more efficacious for BDD
than non-SRI antidepressants or other types of psy-
chotropic medication, although data are limited.
26
Relatively high SRI doses appear to often be needed,
and current recommendations are that the SRI should
be taken for at least 12 weeks before determining
whether it is efficacious.
1,26 At that time, if it is not help-
ful, the SRI should be augmented with another medica-
tion, or the SRI should be switched to a different SRI.
1,115
Successful SRI treatment results in less frequent and
intense appearance preoccupations, decreased BDD-
related distress, less intense urges and less time spent
performing compulsive/safety behaviors, and better con-
trol over BDD preoccupations and compulsions.
26 Most
studies have found that associated symptoms, such as
depressive symptoms, functioning, and quality of life,
often improve as well.
26,116 In addition, most studies have
found that insight regarding the perceived appearance
flaws improves with SRI treatment.
26
Little data are available on the efficacy of antipsychotic
medications for BDD, even though many patients have
delusional BDD beliefs. Several case reports indicate
successful SRI augmentation with an antipsychotic.
117,118
However, a study that examined the efficacy of aug-
menting fluoxetine with pimozide versus placebo found
that pimozide augmentation was not more efficacious
than placebo augmentation.
119The sample size was small
(n=28), raising the possibility of Type II error. However,
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subjects responded to pimozide (versus 17.6% to
placebo), suggesting minimal efficacy for pimozide aug-
mentation. In a small case series of olanzapine augmen-
tation of fluoxetine, BDD symptoms were minimally
improved in 2 of 6 patients, and no patient experienced
more substantial improvement, suggesting that atypical
neuroleptics may not be efficacious for BDD.
120 Other
augmentation strategies have been preliminarily exam-
ined, with data suggesting that buspirone, and occasion-
ally other medications, may be helpful when added to an
SRI.
1,26,114,115
Two open-label studies (n=17 for both studies) suggest
that the serotonin-norepinephrine reuptake inhibitor
venlafaxine or the antiepileptic medication levetirac-
etam may be efficacious for some patients with
BDD.
121,122 While these findings are promising, the small
sample sizes, lack of a control group, and lack of repli-
cation indicate that these medications should not be con-
sidered first-line treatments for BDD at this time.
Cognitive-behavioral therapy
Available research suggests that cognitive-behavioral
therapy (CBT) may be efficacious for BDD.
123-125 Most
studies have examined a combination of cognitive com-
ponents (eg, cognitive restructuring that focuses on
changing appearance-related assumptions and beliefs)
with behavioral components, consisting mainly of expo-
sure and response prevention (ERP) to reduce avoid-
ance and compulsive and safety behaviors. Findings from
neuropsychological research (as reviewed above) sup-
port the use of cognitive-behavioral strategies to help
patients focus less on minor details of their appearance
and to instead view their body more “holistically.”
126
Early case reports indicated that exposure therapy may be
effective.
127,128 In a subsequent series, in which BDD patients
(n=17) received 20 sessions of daily individual 90-minute
CBT, BDD symptom severity significantly decreased.
129 In
an open trial of group CBT (n=13), administered in twelve
90-minute sessions, BDD and depressive symptoms signif-
icantly improved (from severe to moderate).
124 In a study
of ten participants who received thirty 90-minute individ-
ual ERP sessions without a cognitive component, and 6
months of relapse prevention, improvement was main-
tained at up to 2 years.
130
Two waitlist controlled studies have been published.
Veale, Gournay, and colleagues randomized 19 patients
to 12 weekly sessions of individual CBT or a 12-week
no-treatment waitlist control.
123 Two measures of BDD
symptoms showed significant improvement with CBT
compared to the waitlist condition. In a randomized con-
trolled trial of group CBT for BDD, 54 women were
assigned to a CBT treatment group (provided in 8
weekly 2-hour sessions) or to a no-treatment waitlist
control.
131 Subjects who received CBT had significantly
greater improvement in BDD symptoms, self-esteem,
and depression than those on a waiting list with large
effect sizes. Although preliminary, these findings suggest
that CBT is very promising for BDD. 
One challenge when treating patients with CBT is that
many are insufficiently motivated for treatment, because
of poor insight (ie, not accepting that they have a treat-
able psychiatric illness or believing that they need cos-
metic treatment rather than mental health treatment).
Clinical impressions suggest that use of motivational
interviewing techniques may be helpful.
125,132 In addition,
certain BDD symptoms may require specialized tech-
niques, such as the use of habit reversal training for com-
pulsive skin-picking or hair-plucking.
126
At this time it is not known whether medication or CBT
are more efficacious for BDD, as no randomized con-
trolled studies have directly compared them.
Furthermore, it is not known whether a combination of
medication and CBT is more efficacious than either
treatment alone. However, based on clinical experience,
the authors recommend that all patients with severe
BDD, severe depressive symptoms, or active suicidal
ideation receive an SRI and ideally both treatments.
1
Future studies are needed to assess these important
questions. 
Alternative psychosocial treatments
Despite the severe morbidity associated with BDD,
there are few effective treatments and a pressing need
for more treatment options and more treatment
research. Currently, CBT is the only psychosocial treat-
ment with preliminary empirical support. Some patients,
however, refuse CBT or terminate prematurely from
therapy.
133Therefore, alternative treatments are needed.
Interpersonal psychotherapy (IPT) may offer a promis-
ing alternative. Individuals with BDD often have a his-
tory of emotional abuse,
134 long-standing interpersonal
conflicts,
135 and may suffer from crippling social anxiety
and interpersonal problems.
70,71 IPT enables patients to
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sonal distress, poor self-esteem, and depressed mood,
136,137
which are hypothesized to maintain body image con-
cerns. Results from a small open trial pilot (n=9) regard-
ing the preliminary efficacy of IPT for BDD are promis-
ing,
138 and a randomized controlled trial is currently
under way. 
Conclusions
Despite BDD’s prevalence and severity, this disorder
remains underdiagnosed in clinical settings. Given the
markedly poor functioning and quality of life, and high
rates of suicidality, among these patients, it is important
that BDD is recognized and accurately diagnosed.
12,125
Interventional research on BDD is still limited; however,
available treatment data are promising and indicate that
most patients improve with appropriate treatment that
targets BDD symptoms specifically. Limited data exist
regarding BDD in children and adolescents or the
expression of BDD in other cultures. There is emerging
evidence that information processing deficits play an
important role in BDD, but very little is known about
this important topic. It is hoped that further research on
BDD will elucidate the many aspects of this disorder
that remain poorly understood, lead to more effective
treatments and more treatment options, and ultimately
enable prevention of this severe mental disorder. ❏
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Trastorno dismórfico corporal
El trastorno dismórfico corporal (TDC) es una pato-
logía relativamente común que se caracteriza por
una preocupación agobiante o limitante relacio-
nada con defectos leves o imaginarios de la apa-
riencia. Habitualmente se considera el TDC como un
trastorno del espectro obsesivo-compulsivo, dadas
las similitudes que tiene con el trastorno obsesivo-
compulsivo. Es importante reconocer y tratar apro-
piadamente el TDC, ya que este trastorno se asocia
con un marcado deterioro del funcionamiento psi-
cosocial, una muy pobre calidad de vida y alta fre-
cuencia de suicidalidad. En esta revisión se entrega
una panorámica de los hallazgos de la investigación
en el TDC, incluyendo su epidemiología, las carac-
terísticas clínicas, el curso de la enfermedad, la
comorbilidad, el funcionamiento psicosocial y la sui-
cidalidad. También se revisa brevemente la inves-
tigación reciente sobre los sustratos neurales y el
procesamiento cognitivo. Finalmente se discuten las
aproximaciones terapéuticas que parecen eficaces
para el TDC, con un foco en los inhibidores de la
recaptura de serotonina y la terapia cognitivo-con-
ductual. 
Trouble dysmorphophobique
Le trouble dysmorphophobique est un trouble rela-
tivement courant consistant en une préoccupation
pénible ou obsédante concernant une imperfection
légère ou imaginaire de l’apparence. La dysmor-
phophobie est considérée couramment comme un
trouble du spectre obsessionnel-compulsif (TOC),
fondé sur ses ressemblances avec le TOC. Il est
important de le reconnaître et de le traiter correc-
tement, ce trouble étant associé à une altération
importante du fonctionnement psychosocial, en
particulier une mauvaise qualité de vie et un taux
élevé de suicides. Cet article présente les travaux sur
le trouble dysmorphophobique, incluant son épi-
démiologie, son tableau clinique, l’évolution de la
maladie, la comorbidité, le fonctionnement psy-
chosocial et le taux de suicide. Nous présentons
également rapidement les résultats de recherche
récente sur les substrats neuraux et les processus
cognitifs. Nous abordons finalement les traitements
qui semblent efficaces pour cette pathologie, en
mettant l’accent sur les inhibiteurs de la recapture
de la sérotonine et le traitement cognitivo-com-
portemental. 
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